Self-learning AI accelerates drug development in cancer research
CompanyReverie Labs, Cambridge (Massachussetts), USA
The company Reverie Labs specializes in the development of AI-based software programs to accelerate and optimize drug development. To do this, the company combines different technological approaches that enable a predictive calculation of the efficacy and toxicity of compounds to be tested. To generate the predictions, the systems rely on information from huge, biochemically and physiologically relevant data sets. The programs also work on the principle of machine learning; i.e. they recognize new relevant compounds and mechanisms of action and automatically integrate them into their future calculations. This means that the programs continue to optimize themselves in an ongoing process. In addition, the platforms can help advance personalized medicine, as they are also able to process patient-specific data and take individual characteristics into account in their predictions. The method can be used in various approaches to drug development, such as evaluating the efficacy and safety of new drugs or generating information on the absorption, distribution, metabolism and excretion (ADME behaviour) of certain active ingredients. A particular focus of the company is the development of kinase inhibitors that are used to treat cancer. In summary, the AI-based programs prove to be a valuable and advanced method that can help accelerate (personalized) drug development and improve existing drug treatment options.
Pioneering new technology to develop next-generation cancer therapies
contact@reverielabs.com
Added on: 11-08-2023
[1] https://www.reverielabs.com/
